What is the Wegovy pill?
The Wegovy pill is a daily tablet that contains the drug semaglutide, the same medication found in injectable Wegovy.
It works the same way as the injection: by mimicking the GLP-1 hormone that our gut releases after a meal, which reduces appetite and slows digestion.1
People often describe this effect as ‘quieting the food noise’, the constant background thoughts about food that ease with a GLP-1 medication.
Instead of a weekly injection, you swallow the tablet first thing in the morning on an empty stomach with a small amount of water.
Each tablet contains an absorption enhancer called SNAC (salcaprozate sodium). SNAC protects the semaglutide from stomach acid and helps it cross the stomach lining into the bloodstream.3
The pill comes in four strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg. You start on the lowest dose and increase every 30 days over a 12-week escalation period, reaching the maintenance dose of 25 mg.
Is the Wegovy pill available in the UK?
The Wegovy pill is now available in the UK. The MHRA approved it on 11 June 2026, the first GLP-1 weight-loss tablet to be licensed in the country.8
It’s available privately on prescription, including through Second Nature, in the same way injectable Wegovy and Mounjaro first reached UK patients.
It isn’t available on the NHS yet. NHS funding is a separate decision made by the National Institute for Health and Care Excellence (NICE), which has not recommended oral semaglutide for weight management.
For now, that means access is private. Injectable Wegovy (2.4 mg and 7.2 mg) and injectable Mounjaro (tirzepatide) also remain available, both privately and, in some cases, through the NHS.
The pill is licensed for adults with obesity (a BMI of 30 or above), or who are overweight (a BMI of 27 to 30) with at least one weight-related condition, alongside a reduced-calorie diet and more physical activity.8
How effective is the Wegovy pill?
The main evidence comes from the OASIS 4 trial, published in the New England Journal of Medicine in September 2025.1
OASIS 4 enrolled 307 adults living with obesity or overweight (with at least one weight-related condition) who didn’t have type 2 diabetes.
Participants received either oral semaglutide 25 mg or a placebo once daily for 71 weeks, alongside lifestyle changes, with the primary weight outcome measured at week 64.
The headline result was an average weight loss of 13.6% with oral semaglutide, compared with 2.2% with placebo.1
The proportion of participants reaching each weight-loss threshold:
| Weight loss achieved |
Wegovy pill (25 mg) |
Placebo |
| 5% or more |
76.3% |
31% |
| 10% or more |
60% |
14% |
| 15% or more |
47% |
6% |
| 20% or more |
30% |
3% |
Among participants who completed the full course at the maintenance dose, average weight loss reached 16.6%.1
OASIS 4 also reported improvements in waist circumference, HbA1c, blood lipids, and C-reactive protein, which are the cardiometabolic measures that explain why semaglutide reduces cardiovascular risk in trials of the injectable form.1
These results are broadly comparable to injectable Wegovy 2.4 mg, which produced an average weight loss of 14.9% over 68 weeks in STEP 1.4
A separate trial (OASIS 1) tested a 50 mg oral dose and found an average weight loss of 15.1%, though this dose isn’t approved.5
How the Wegovy pill compares to injectable Wegovy
|
Wegovy pill |
Injectable Wegovy (2.4 mg) |
Injectable Wegovy (7.2 mg) |
| Drug |
Semaglutide |
Semaglutide |
Semaglutide |
| How you take it |
A daily tablet on an empty stomach |
Injection once a week |
Injection once a week |
| Maintenance dose |
25 mg once a day |
2.4 mg once a week |
7.2 mg once a week |
| Average weight loss |
13.6% (OASIS 4)1 |
14.9% (STEP 1)4 |
20.7% (STEP UP)7 |
| Time to maintenance dose |
About 12 weeks |
About 16 weeks |
About 28 weeks |
| UK availability |
Available privately |
Available now |
Available now (MHRA approved January 2026) |
| Common side effects |
Nausea, diarrhoea, vomiting |
Nausea, diarrhoea, constipation |
Nausea, diarrhoea, constipation |
The weight loss results across formulations are broadly comparable, although the 7.2 mg injectable dose produces greater weight loss than either the pill or the 2.4 mg injection.
How much does the Wegovy pill cost in the UK?
The Wegovy pill is only available privately in the UK and isn’t funded on the NHS because NICE hasn’t yet reviewed it for the NHS. That means there’s no fixed price, and the cost depends on the provider you choose.
At Second Nature, the monthly price rises with the dose. A 12-month plan lowers the cost compared with paying month-to-month. All prices also include £50 off your first month.
| Wegovy pill dose |
Monthly plan (per month) |
12-month plan (per month) |
| 1.5 mg (starting dose) |
£149 |
£149 £124 |
| 4 mg |
£179 |
£179 £154 |
| 9 mg |
£199 |
£199 £174 |
| 25 mg (maintenance dose) |
£229 |
£229 £204 |
You start on the 1.5 mg dose and can build up to the 25 mg maintenance dose over about 12 weeks, so the early months cost less than the full dose.
However, we recommend staying on the lowest dose for as long as possible. Each month, the clinical team reviews your progress, and the dose will increase only if needed.
The 12-month plan is cheaper each month than the rolling monthly plan, in return for committing upfront.
Prices vary among private providers, and injectable Wegovy is in a similar range, at around £150 to £250 a month.
Any NHS price would depend on a future NICE appraisal.
Wegovy pill on the NHS
NHS access to the Wegovy pill depends on two things: MHRA approval and a positive NICE recommendation.
The MHRA approved the pill on 11 June 2026, which makes it legal to prescribe privately in the UK.8
NHS funding is a separate decision. NICE assesses whether the NHS should fund a medication by weighing its cost against the health benefit it produces.
NICE has not recommended oral semaglutide for weight management, so the Wegovy pill isn’t available on the NHS. Any NHS access would depend on a future NICE appraisal.
In the meantime, injectable Wegovy is available on the NHS for adults living with obesity (or overweight with a weight-related condition) who meet the NICE eligibility criteria, typically through specialist services.
Side effects of the Wegovy pill
The side effects of the Wegovy pill are similar to those of injectable Wegovy and mostly affect the digestive system.
In OASIS 4, 74% of participants on the pill had gastrointestinal side effects, compared to 42% on placebo.1
The most common were nausea, diarrhoea, and vomiting, and most cases were mild to moderate, worsening during dose increases and improving as the body adjusts.
Serious adverse events were actually less common with oral semaglutide (3.9%) than with placebo (8.8%) in OASIS 4.1
The Wegovy pill carries the same warning as injectable Wegovy about thyroid C-cell tumours, based on animal studies. This risk hasn’t been confirmed in humans, but the medication isn’t recommended for anyone with a personal or family history of medullary thyroid carcinoma.
Taking the tablet correctly, on an empty stomach with only a small amount of water, helps absorption and may reduce stomach discomfort.
How to take the Wegovy pill
The Wegovy pill needs a specific daily routine to work properly.
Semaglutide is a peptide, a chain of amino acids that would normally be broken down by stomach acid before it could be absorbed. The SNAC enhancer in each tablet helps prevent this, but only when the stomach is empty.3
The daily routine:
- Take one tablet first thing in the morning, on an empty stomach
- Swallow the tablet whole with no more than half a glass of plain water (up to 120 ml)
- Don’t use any other liquid besides water
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
- Don’t crush, split, or chew the tablet
If you miss a dose, skip it and take your next dose the following day as normal. Don’t take two tablets in one day.
Some people find that a weekly injection slots into their routine more easily than remembering to take a pill every day, on an empty stomach, before the rest of the day starts.
What the 30-minute fast means for other medications you take
The 30-minute fasting window applies to other oral medications, too, not just food. This is most relevant for medications that are themselves taken in the morning on an empty stomach:
- Levothyroxine (for hypothyroidism): the standard advice is to take it on an empty stomach 30 to 60 minutes before food or other tablets. Combining it with Wegovy requires prescriber input on the order to protect the absorption of both medications.
- Oral HRT and the combined contraceptive pill: GLP-1 medications can slow stomach emptying, which may reduce absorption of other oral medications. Use additional contraception if you experience vomiting or diarrhoea.
- Warfarin and other anticoagulants: the fasting window isn’t the main concern, but rapid changes in food intake and weight while taking a GLP-1 medication can affect how warfarin works. If you take warfarin, you’ll need closer INR monitoring during the first few months.
Talk to your prescriber before starting if you take any daily oral medication. The 30-minute window can usually be planned around, but it’s worth getting the timing right from the start.
Wegovy pill vs Rybelsus
The Wegovy pill and Rybelsus both contain oral semaglutide, but they’re different products approved for different purposes at different doses.
Rybelsus (up to 14 mg) is licensed in the UK for the treatment of type 2 diabetes and is available on the NHS.
The Wegovy pill (25 mg) is licensed for weight management at a higher dose and is now available in the UK.
At Rybelsus doses, weight loss is modest, typically 2 to 4 kg over 6 to 12 months in type 2 diabetes trials.
The higher 25 mg dose in the Wegovy pill is what produces the 13.6% average weight loss reported in OASIS 4.1
If you’re already on Rybelsus for type 2 diabetes, the Wegovy pill isn’t an additional treatment you can combine it with. They’re the same drug at different doses, and a switch would need prescriber input.
Wegovy pill alternatives in the UK
The Wegovy pill is now one of several GLP-1 medications licensed in the UK for weight loss. The others are:
- Injectable Wegovy 2.4 mg: once-a-week injection. Average weight loss of 14.9% over 68 weeks in STEP 1.4
- Injectable Wegovy 7.2 mg: higher-dose injection, MHRA-approved January 2026. Average weight loss of 20.7% over 72 weeks in STEP UP.7
- Injectable Mounjaro (tirzepatide): once-a-week injection. Average weight loss of 22.5% at the 15 mg dose in SURMOUNT-1.
Another oral option, Foundayo (orforglipron), was FDA-approved in April 2026 and is in MHRA review.
Foundayo is the first non-peptide oral GLP-1, so it doesn’t need the fasting window.
UK availability is expected in 2027. For a side-by-side comparison, see our guide on the Wegovy pill vs Foundayo.
Who might benefit from the Wegovy pill?
The Wegovy pill could be useful for people who’ve avoided GLP-1 treatment because they’re uncomfortable with injections.
Needle aversion is a common reason people delay starting a GLP-1 medication, and an oral alternative removes that barrier.
It may also suit people who travel frequently and find a daily tablet easier to manage than carrying injection pens that may need refrigeration.
For people who are already managing well on injectable Wegovy or Mounjaro, there may be no good reason to switch.
The daily fasting window and 30-minute wait before eating may feel less convenient than a weekly injection.
For people who’d prefer an oral medication without the fasting rules, Foundayo is likely to be the better fit once it reaches the UK.
Wondering if the Wegovy pill is right for you? Use the eligibility checker at the top of the page to see how your BMI compares with the UK prescribing criteria, then take our 3-minute quiz to find out if you can start with Second Nature.
Frequently asked questions
Is the Wegovy pill as effective as the injection?
Clinical trial results suggest the weight loss is broadly comparable with the 2.4 mg dose of injectable Wegovy.
The pill achieved an average weight loss of 13.6% over 64 weeks in OASIS 4,1 while injectable Wegovy 2.4 mg achieved 14.9% over 68 weeks in STEP 1.4
Among participants who completed the full course of the pill, the average weight loss was 16.6%.1
Can you get the Wegovy pill in the UK?
Yes. The MHRA approved the Wegovy pill on 11 June 2026, and it’s available privately on prescription, including through Second Nature.8
It isn’t available on the NHS yet, as NICE hasn’t recommended it for weight management.
What doses does the Wegovy pill come in?
The pill comes in 1.5 mg, 4 mg, 9 mg, and 25 mg strengths. Treatment starts at 1.5 mg and increases every 30 days (if needed) until it reaches the 25 mg maintenance dose at around 12 weeks.
Will the Wegovy pill be available on the NHS?
Not currently. NICE hasn’t recommended oral semaglutide for weight management, so NHS funding isn’t available.
Any future NHS access would depend on a NICE appraisal. Private providers offer it now.
Is there a Mounjaro pill?
No. Tirzepatide, the drug in Mounjaro, isn’t available as a tablet. Its molecular structure makes it difficult to formulate as an oral medication.
Eli Lilly has instead developed orforglipron (Foundayo), a separate oral GLP-1 medication that was approved by the FDA in April 2026.
Can you switch from injectable Wegovy to the pill?
This would need to be discussed with your prescriber. The two formulations use different doses and schedules, daily versus weekly, so switching needs clinical guidance on timing and dose adjustment.
If you’re already on the 2.4 mg weekly injection, you can usually move across to the 25 mg daily tablet, with your prescriber confirming the timing.
How much does the Wegovy pill cost in the UK?
The Wegovy pill will cost between £149 and £229 with Second Nature, depending on the dose.
Other private providers are likely to offer the medication at similar prices, depending on the level of support available alongside the drug.
What are the side effects of the Wegovy pill?
The most common side effects are nausea, diarrhoea, and vomiting.
In OASIS 4, 74% of participants experienced gastrointestinal side effects, compared to 42% on placebo.1
Most cases were mild to moderate and improved as the body adjusted during the dose-escalation phase.
Take home message
The Wegovy pill is the first oral GLP-1 medication approved specifically for weight loss.
Trial results show weight-loss outcomes broadly comparable to those of injectable Wegovy 2.4 mg, making it a practical alternative for people who prefer tablets to injections.
The pill is now available privately in the UK after MHRA approval on 11 June 2026, including through Second Nature.8 It isn’t available on the NHS yet.
If you’d like to find out whether the Wegovy pill could be right for you, use the eligibility checker at the top of the page.
Injectable Wegovy and Mounjaro are also available in the UK and are supported by strong evidence for weight loss.
Second Nature’s published research shows that members taking semaglutide alongside dietitian-led behaviour change support achieved an average weight loss of 19.1% at 12 months, with 77.7% achieving 10% or more weight loss.6
Second Nature's Mounjaro and Wegovy programmes
Second Nature provides Mounjaro or Wegovy as part of our Mounjaro and Wegovy weight-loss programmes.
Why choose Second Nature over other medication providers, assuming you're eligible?
Because peace of mind matters.
We've had the privilege of working with the NHS for over eight years, helping people across the UK take meaningful steps toward a healthier, happier life.
Our programmes are designed to meet people where they are, whether that means support with weight loss through compassionate one-to-one health coaching, or access to the latest weight-loss medications (like Mounjaro and Wegovy) delivered alongside expert care from a multidisciplinary team of doctors, psychologists, dietitians, and personal trainers.
At the heart of everything we do is a simple belief: real, lasting change comes from building better habits, not relying on quick fixes. We're here to support that change every step of the way.
With over a decade of experience, thousands of lives changed, and a long-standing record of delivering programmes used by the NHS, we believe we're the UK's most trusted weight-loss programme.
We hope to offer you something invaluable: peace of mind, and the support you need to take that first step.
